Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.54 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573987 | 1.00 | MMP1 (0.57) | MMP1MMP3MMP9MAPTTDP1 | |
| SCHEMBL6218963 | 0.86 | ATM (0.62) | POLBATMALDH1A1 | |
| SCHEMBL13524950 | 0.86 | ATM (0.62) | POLBATMALDH1A1 | |
| SCHEMBL15630652 | 0.86 | MAPT (0.60) | MMP1MMP3MMP9MAPTTDP1 | |
| SCHEMBL13645698 | 0.86 | MAPT (0.60) | MMP1MMP3MMP9MAPTTDP1 | |
| SCHEMBL22352567 | 0.84 | TACR1 (0.54) | POLBATMALDH1A1 | |
| SCHEMBL8980296 | 0.84 | TACR1 (0.54) | POLBATMALDH1A1 | |
| SCHEMBL18435382 | 0.83 | CTSS (0.68) | MMP1MMP3MMP9MAPTTDP1 | |
| SCHEMBL16459753 | 0.83 | CTSS (0.68) | MMP1MMP3MMP9MAPTTDP1 | |
| SCHEMBL16459752 | 0.83 | CTSS (0.68) | MMP1MMP3MMP9MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709644-B2 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20070213536-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| EP-1375501-B1 | Process for enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo(4.3.0)nonane using simulated moving bed chromatography | LANXESS DEUTSCHLAND GMBH (DE) | 2005-11-02 | — | — | EP | disclosed |
| US-20040044205-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1375501-A1 | Process for enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo(4.3.0)nonane using simulated moving bed chromatography | Bayer Chemicals AG (DE) | 2004-01-02 | — | — | EP | disclosed |
| EP-0545168-B1 | Optically active polymer beads containing a filler | BAYER AG (DE) | 1996-04-24 | — | — | EP | disclosed |
| EP-0379917-B1 | Optically active (meth)acrylic-acid derivatives, their preparation, their polymerisation into optically active polymers and their use | BAYER AG (DE) | 1995-08-09 | — | — | EP | disclosed |
| US-5348656-A | Adsorbants for optical resolution | BAYER AKTIENGESELLSCHAFT (DE) | 1994-09-20 | — | — | US | disclosed |
| US-5274167-A | A N-(meth)acryloyl amino acid amide | BAYER AKTIENGESELLSCHAFT (DE) | 1993-12-28 | — | — | US | disclosed |
| EP-0545168-A1 | Optically active polymer beads containing a filler | BAYER AG (DE) | 1993-06-09 | — | — | EP | disclosed |
| EP-0379917-A2 | Optically active (meth)acrylic-acid derivatives, their preparation, their polymerisation into optically active polymers and their use | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044205-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | CYP1B1, DECR1, SPIN2B | MMP1 3631/4885MMP3 4134/4885MMP9 227/4885 |
| US-20070213536-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | CYP1B1, CYP8B1, CCR8 | MMP1 3980/4885MMP3 3745/4885MMP9 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.